SCM
SLN

Soleus Capital Management’s Silence Therapeutics SLN Stock Holding History

Soleus Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.92M Buy
+630,000
New +$4.43M 0.24% 68
2024
Q4 		– Sell
-260,000
Closed -$4.73M – 103
2024
Q3 		$4.73M Buy
+260,000
New +$4.84M 0.37% 62

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Soleus Capital Management's SLN Position: Q2 2026 in Review

Soleus Capital Management opened a new position in Silence Therapeutics (SLN) in Q2 2026: 630,000 shares worth $6.92M. The stake represents 0.24% of the portfolio and ranks #68 among its holdings. This is a return to the name: Soleus Capital Management previously reported a position in SLN as recently as Q3 2024.

Soleus Capital Management first reported a position in SLN in Q3 2024 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Soleus Capital Management held 630,000 shares of Silence Therapeutics worth $6.92M as of Q2 2026.
  • Silence Therapeutics was a new Soleus Capital Management position in Q2 2026.
  • Silence Therapeutics made up 0.24% of Soleus Capital Management's portfolio in Q2 2026, its #68 holding.
  • Soleus Capital Management first reported a position in Silence Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.